Articles by Heather A. Wakelee

Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.